| FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes EJ Adams, WR Karthaus, E Hoover, D Liu, A Gruet, Z Zhang, H Cho, ... Nature 571 (7765), 408-412, 2019 | 195 | 2019 |
| The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target SG Zhao, J Lehrer, SL Chang, R Das, N Erho, Y Liu, M Sjöström, RB Den, ... JNCI: Journal of the National Cancer Institute 111 (3), 301-310, 2019 | 163 | 2019 |
| Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer A Necchi, D Raggi, A Gallina, JS Ross, E Farè, P Giannatempo, ... European urology 77 (6), 701-710, 2020 | 142 | 2020 |
| Impact of immune and stromal infiltration on outcomes following bladder-sparing trimodality therapy for muscle-invasive bladder cancer JA Efstathiou, KW Mouw, EA Gibb, Y Liu, CL Wu, MR Drumm, JB da Costa, ... European urology 76 (1), 59-68, 2019 | 136 | 2019 |
| Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG/RTOG 9601 randomized clinical trial FY Feng, HC Huang, DE Spratt, SG Zhao, HM Sandler, JP Simko, ... JAMA oncology 7 (4), 544-552, 2021 | 99 | 2021 |
| Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer DE Spratt, M Alshalalfa, N Fishbane, AB Weiner, R Mehra, BA Mahal, ... Clinical Cancer Research 25 (22), 6721-6730, 2019 | 85 | 2019 |
| MYC drives aggressive prostate cancer by disrupting transcriptional pause release at androgen receptor targets X Qiu, N Boufaied, T Hallal, A Feit, A de Polo, AM Luoma, W Alahmadi, ... Nature communications 13 (1), 2559, 2022 | 72 | 2022 |
| Plasma cells are enriched in localized prostate cancer in Black men and are associated with improved outcomes AB Weiner, T Vidotto, Y Liu, AA Mendes, DC Salles, FA Faisal, S Murali, ... Nature communications 12 (1), 935, 2021 | 68 | 2021 |
| Factors associated with methadone maintenance therapy discontinuation among people who inject drugs A Lo, T Kerr, K Hayashi, MJ Milloy, E Nosova, Y Liu, N Fairbairn Journal of substance abuse treatment 94, 41-46, 2018 | 67 | 2018 |
| Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences W Rayford, AT Beksac, J Alger, M Alshalalfa, M Ahmed, I Khan, ... Communications biology 4 (1), 670, 2021 | 60 | 2021 |
| Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer S Awasthi, A Berglund, J Abraham-Miranda, RJ Rounbehler, K Kensler, ... Clinical Cancer Research 27 (1), 320-329, 2021 | 59 | 2021 |
| Clinical and genomic implications of luminal and basal subtypes across carcinomas SG Zhao, WS Chen, R Das, SL Chang, SA Tomlins, J Chou, DA Quigley, ... Clinical cancer research 25 (8), 2450-2457, 2019 | 57 | 2019 |
| Novel RB1-loss transcriptomic signature is associated with poor clinical outcomes across cancer types WS Chen, M Alshalalfa, SG Zhao, Y Liu, BA Mahal, DA Quigley, T Wei, ... Clinical Cancer Research 25 (14), 4290-4299, 2019 | 49 | 2019 |
| Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis JJ De Jong, Y Liu, AG Robertson, R Seiler, CS Groeneveld, ... Genome medicine 11, 1-13, 2019 | 44 | 2019 |
| Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer V Genitsch, A Kollár, G Vandekerkhove, J Blarer, M Furrer, M Annala, ... Urologic Oncology: Seminars and Original Investigations 37 (11), 826-836, 2019 | 37 | 2019 |
| Validation of the Decipher test for predicting distant metastatic recurrence in men with high-risk nonmetastatic prostate cancer 10 years after surgery T Van den Broeck, L Moris, T Gevaert, L Tosco, E Smeets, N Fishbane, ... European urology oncology 2 (5), 589-596, 2019 | 29 | 2019 |
| Can patients with muscle-invasive bladder cancer and fibroblast growth factor receptor-3 alterations still be considered for neoadjuvant pembrolizumab? A comprehensive … A Necchi, D Raggi, P Giannatempo, L Marandino, E Farè, A Gallina, ... European urology oncology 4 (6), 1001-1005, 2021 | 25 | 2021 |
| Association of molecular subtypes with differential outcome to apalutamide treatment in nonmetastatic castration-resistant prostate cancer FY Feng, S Thomas, F Saad, M Gormley, KY Margaret, DS Ricci, ... JAMA oncology 7 (7), 1005-1014, 2021 | 25 | 2021 |
| Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer D Liu, MA Augello, I Grbesa, D Prandi, Y Liu, JE Shoag, RJ Karnes, ... The Journal of clinical investigation 131 (10), 2021 | 24 | 2021 |
| Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy P Grivas, TA Bismar, AS Alva, HC Huang, Y Liu, R Seiler, N Alimohamed, ... Urologic Oncology: Seminars and Original Investigations 38 (4), 262-268, 2020 | 24 | 2020 |
Elai DavicioniVeracyteVerified email at veracyte.com
